Boehringer Ingelheim Announces Plans to Advance Ne...
Category : Clinical Trial Update 10 September 2024Boehringer Ingelheim announces plans to advance potential new treatment for geographic atrophy, foll...
Boehringer Ingelheim announces plans to advance potential new treatment for geographic atrophy, foll...
Daiichi Sankyo and AstraZeneca's New TROP2 Biomarker Predicts Datopotamab Deruxtecan Outcomes in...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX-121 to treat patients...
Overview Merck, known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned...
Sanofi’s HERCULES phase 3 study of tolebrutinib to treat non-relapsing secondary progressive M...